Mokalla et al. synthesize 269 references on influenza vaccine platforms (live attenuated, inactivated split/whole, recombinant HA), adjuvants (alum, MF59, AS03, AF03, virosomes, CAF01, TLR agonists, saponins, enterotoxins, physical adjuvants), and universal-vaccine strategies (mRNA, chimeric HA, NP/M1/M2 targets). The review correctly emphasizes that seasonal VE is strain-dependent, citing 2021β22 Europe data of 79% VE against A/H1N1 versus 36% against A/H3N2, and only ~14% adjusted VE against H3N2 in adults during a mismatch, alongside the 2014β15 season where H3N2 VE was 6% overall .
The strongest quantitative signal for adjuvant benefit comes from pediatric trials: MF59-adjuvanted TIV achieved 86% absolute efficacy versus 43% for non-adjuvanted TIV in children aged 6β72 months across two seasons . However, the key MF59 reviews carry declared Novartis affiliations, a sponsor-bias risk the review does not flag .
It is a narrative review without systematic search, PRISMA methods, or effect-size synthesis; several claims rest on single animal studies (e.g., pig nanoparticle platforms, Nano-11, chitosan) with modest viral-load reductions. The review does report the AS03/Pandemrix narcolepsy signal in Swedish and Finnish adolescents, attributing it plausibly to molecular mimicry between H1N1 antigen and hypocretin rather than the adjuvant alone . The universal-vaccine section acknowledges genuine translational failures (MVA-NP+M1 Phase IIb missed endpoints) β a commendably honest inclusion. Notably, newer preclinical adjuvant data (BECC adjuvants, bacterial membrane-derived adjuvants for intranasal NA vaccines) were published in 2025 and would strengthen but do not appear in the cited evidence base .
Confidence note: Conclusions about current licensed vaccines are well-grounded; claims about adjuvanted cross-protection translating to human breadth remain uncertain pending phase-3 outcome trials.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.